• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » TranS1 announces $20 million public stock offering for spinal surgery devices | Funding Roundup

TranS1 announces $20 million public stock offering for spinal surgery devices | Funding Roundup

September 21, 2011 By MassDevice staff

TranS1

Lumbar spine surgery company TranS1 Inc. (NSDQ:TSON) priced a public offering of 6.2 million shares of common stock at $3.25 per share, expecting to raise up to $20.2 million.

TranS1 plans to use the funds for additional clinical trials, reimbursement efforts, sales personnel, research and product development activities and working capital, according to SEC filings. It added that funds may go toward acquisition of or investment in technologies, products or assets that complement the business.

Investment in TranS1 is a risky venture, the company reported. Although its spinal surgery products won FDA 510(k) clearance, long-term efficacy hasn’t been demonstrated through clinical trials.

Adding another layer of risk is that sales depend largely on third-party coverage and reimbursement. Reimbursement for TranS1’s products was complicated by a billing re-coding in 2009 which placed them in Category III alongside products often considered "experimental" or "investigational," according to SEC filings.

"This uncertainty around the availability and amount of reimbursement has caused some physicians to revert to other fusion surgeries where coverage and reimbursement are more certain," TranS1 wrote.

A billing code panel will review the categorization and consider bumping some of TranS1’s products to Category I in October.

The Wilmington, N.C.-based spine fusion company expects the offering to open Monday.

Funding

Here’s a roundup of other dealflow and investment news:

  • Practice Fusion lands $6 million funding round
  • Simpirica Spine closes $22 million in Series C
  • Surgimatrix hopes for $500,000 equity round
  • Fresenius notes offering get Ba2 rating from Moody’s
  • UMass Amherst lands $20 million federal grant
  • HealthTech Capital doles out $800,000 to two companies

  • Teladoc lands $18.6 million funding round
  • Sterionics and Biolectrics land LCCC Innovation Fund grants

  • Non-Invasive Monitoring Systems announces $50K promissory note
  • Mill Creek Life Sciences hopes for $1.5 million round
  • Glucotec raises $8 million of a $10 million round

  • BioBehavioral Diagnostics looks for another $2.4 million to close a $5.5 million round
  • Medical Imaging & Technology Alliance lands $200,000 in federal funding

Filed Under: Funding Roundup, News Well, Spine Tagged With: Baxano Surgical, BioBehavioral Diagnostics Co., Biolectrics LLC, Fresenius, Glucotec Inc., HealthTech Capital, Medical Imaging & Technology Alliance (MITA), Mill Creek Life Sciences LLC, Non-Invasive Monitoring Systems Inc., Practice Fusion, Simpirica Spine Inc., Sterionics Inc., Surgimatrix Inc., Teladoc, University of Massachusetts

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy